Semaglutide News and Research

Latest Semaglutide News and Research

New insights into screening and treatment for diabetic retinal disease

Diabetes affects more than 1 in 10 adults worldwide and has been accompanied by an increase in vision-threatening diabetic retinal disease.

12 Mar 2025

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The study highlights Tirzepatide’s potential as an effective off-label obesity treatment before its formal FDA approval for weight loss.

11 Mar 2025

Integrated anti-aging strategy could reduce neurodegeneration

Aging significantly impacts neurodegeneration, increasing risks for diseases like Alzheimer's. Research focuses on therapies to enhance cognitive function.

11 Mar 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Naturally occurring molecule suppresses appetite and promotes weight loss

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight.

6 Mar 2025

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

5 Mar 2025

Surgery first strategy could lead to better weight loss outcomes

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes.

5 Mar 2025

New study confirms GLP-1 medications are safe for mental health in diabetes

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 diabetes patients.

2 Mar 2025

New study identifies brain circuit key to reducing cocaine-seeking behavior

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.

27 Feb 2025

Genetic study demonstrates fat-selective weight loss with GLP-1 agonist use

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms.

25 Feb 2025

Understanding the impact of weight loss medications on female reproductive health

In recent months, the efficacy of contraception for people taking weight loss medications has been questioned, as several women claim to have gotten pregnant despite using oral contraceptives.

21 Feb 2025

Regulatory crackdown on online prescriptions of weight-loss drugs

Online pharmacies must now conduct in-person consultations before dispensing weight-loss medications, ensuring safe and appropriate use of high-risk drugs.

19 Feb 2025

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.

19 Feb 2025

New gene switch may lead to precise treatments for metabolic diseases

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin.

17 Feb 2025

Diabetes drugs may boost brain health but experts warn of risks

Researchers reviewed 374 studies to explore how GLP-1RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

16 Feb 2025

Low-dose semaglutide reduces alcohol consumption and cravings in early trial

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

13 Feb 2025

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

12 Feb 2025

Vision loss risks in patients using popular GLP-1 medications raise concerns

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established. That is the conclusion of a retrospective study published online on Jan. 30 in JAMA Ophthalmology.

7 Feb 2025

Communication between body muscle and pituitary gland may play unexpected role in female fertility

A newly discovered line of communication between body muscle and the pituitary gland may play an unexpected role in female fertility, according to a new study.

6 Feb 2025

GLP-1 drug exenatide shows no benefit for Parkinson's in new study

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

4 Feb 2025